<DOC>
	<DOCNO>NCT02111317</DOCNO>
	<brief_summary>The purpose study evaluate effect verapamil , P-glycoprotein ( P-gp ) inhibitor , pharmacokinetics ASP015K . This study also assess safety tolerability ASP015K administer alone also combination verapamil .</brief_summary>
	<brief_title>A Study Evaluate Effect Verapamil Pharmacokinetics ASP015K Healthy Adult Subjects</brief_title>
	<detailed_description>Eligible subject admit clinical unit day -1 remain confined day 15 .</detailed_description>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Subject Body Mass Index ( BMI ) range 18.532.0 kg/m2 , inclusive , must weigh least 50 kg Subject must capable swallow multiple tablet Subject agree participate another investigational study treatment Subject know suspected hypersensitivity verapamil , ASP015K , component formulation use . Subject liver function test upper limit normal ( ULN ) Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) Subject history evidence clinically significant cardiovascular , GI , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory ) infection , fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject clinically significant abnormality follow physical examination , ECG , sick sinus syndrome , second thirddegree atrioventricular block , atrial flutter/atrial fibrillation , clinical laboratory test Subject mean pulse &lt; 50 &gt; 90 beat per minute ( bpm ) ; mean systolic blood pressure ( SBP ) &lt; 100 &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &lt; 60 &gt; 90 mmHg ( measurement take triplicate subject rest sit position 5 minute ) Subject mean QTcF interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) Subject use prescribed nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's Wort ) 2 week prior study drug administration , exception hormone replacement therapy ( HRT ) intermittent acetaminophen ( 2 g per day ) Subject smoke use tobaccocontaining product nicotine nicotinecontaining product past 6 month Subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical substance abuse within past 2 year prior screen ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) Subject positive test alcohol , drug abuse , cotinine Subject anticipates inability abstain xanthine ( e.g. , caffeine ) , grapefruit , Seville orange ( include marmalade ) , star fruit , product contain item 72 hour prior day 1 throughout duration study Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) past 3 month prior day 1 Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within past 7 day Subject positive test hepatitis B surface antigen ( HBsAg ) , antihepatitis A virus ( Immunoglobulin [ Ig ] M ) , antihepatitis C virus ( HCV ) , hepatitis B core antibody antihuman immunodeficiency virus ( HIV ) type 1 type 2 Subject positive tuberculosis ( TB ) skin test , Quantiferon Gold® test TSPOT® test Subject receive vaccine within 60 day prior study drug administration Subject absolute neutrophil count ( ANC ) &lt; 2000 cells/mm3 creatine phosphokinase ( CPK ) &gt; 1.5 x ULN Subject major gastrointestinal ( GI ) surgery medical condition , may inhibit absorption and/or metabolism study drug Subject participate interventional clinical study treat investigational drug within 30 day 5 halflives drug , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>